کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8715277 | 1587483 | 2018 | 15 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
TCSoncostatin M receptor βT helper 2EASITh2T helperJanus kinase - کیناز جانوس c-Jun N-terminal kinase - C-Jun N-terminal kinaseSTAT - آمارInvestigator's Global Assessment - ارزیابی جهانی محققIgA - ایمونوگلوبولین IgA interleukin - اینترلوکینAtopic dermatitis - درماتیت آتوپیکDipeptidyl peptidase-4 - دیپپتیدیل پپتیداز 4STAT signal transducer and activator of transcription - مبدل سیگنال STAT و فعال کننده رونویسیSignal transducer and activator of transcription - مبدل سیگنال و فعال کننده رونویسیvisual analogue scale - مقیاس آنالوگ بصریEczema Area and Severity Index - منطقه اگزما و شاخص شدتJAK - چگونهTopical corticosteroid - کورتیکواستروئید موضعیtopical corticosteroids - کورتیکواستروئیدهای موضعی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
امراض پوستی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis](/preview/png/8715277.png)
چکیده انگلیسی
The interleukin 13 (IL-13) and IL-31 cytokines and inflammatory pathways have been identified as important for the pathophysiology of atopic dermatitis (AD). Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, 2 phase 2 trials have been completed with these antibodies in AD treatment. In both trials, significant reductions of Eczema Area and Severity Index scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in patients with AD. One phase 2 trial has been completed for a humanized antibody against IL-31 receptor alpha, which is 1 subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, Eczema Area and Severity Index scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long-term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe AD.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of the American Academy of Dermatology - Volume 78, Issue 3, Supplement 1, March 2018, Pages S37-S42
Journal: Journal of the American Academy of Dermatology - Volume 78, Issue 3, Supplement 1, March 2018, Pages S37-S42
نویسندگان
Carsten R. MD, Jacob P. MD, PhD, DMSc,